Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yirui Wei
Institution:
The Affiliated Yongchuan Hospital of Chongqing Medical University
Observed institutions:
Capital Medical University,
Beijing Chao-Yang Hospital, Capital Medical University,
The Affiliated Yongchuan Hospital of Chongqing Medical University,
Chongqing Medical University
ORCID:
0009-0001-2963-1557
Observed ORCID:
0009-0001-2963-1557
OpenAlex ID:
A5101328943
Prolonged neoadjuvant hormonal therapy enhances IL-17 A/STAT3-mediated inflammation in prostate cancer
2025
·
Yirui Wei
, Yifan Chu
, et al.
·
Discover Oncology
·
1
PDF
Survival after neoadjuvant versus adjuvant chemotherapy in operable hormone receptor-positive HER2-negative breast cancer
2026
·
Qiao Cheng
, Yirui Wei
, et al.
·
iScience
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in operable breast cancer patients with hormone receptor-positive, HER2-negative
2026
·
Yirui Wei
, Mengyuan Wang
, et al.
·
Frontiers in Oncology
Hematological parameters as predictors of prostate cancer: A study based on multivariable and bidirectional Mendelian randomization
2025
·
Yirui Wei
, Hao Wang
, et al.
·
Medicine
A Retrospective Cohort Study on Long-Term Results of Neoadjuvant Versus Adjuvant Chemotherapy Among HR+/HER2- Breast Cancer Patients
2025
·
Lu Gan
, Yirui Wei
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
5
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type